| 冯 芬,胡 斌,招丽蓉,徐绮华,林秀强,林 奔,王 巍.血清VEGF水平与贝伐珠单抗联合化疗治疗转移性结直肠癌患者疗效的关系研究[J].现代生物医学进展英文版,2017,17(31):6136-6139. |
| 血清VEGF水平与贝伐珠单抗联合化疗治疗转移性结直肠癌患者疗效的关系研究 |
| Metastasis Colorectal Cancer: Effects of Serum VEGF and Bevacizumab Combined with Chemotherapy |
| Received:March 16, 2017 Revised:April 13, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.31.032 |
| 中文关键词: 转移性结直肠癌 血管内皮生长因子 化疗 贝伐珠单抗 |
| 英文关键词: Metastatic colorectal cancer Vascular endothelial growth factor Chemotherapy Bevacizumab |
| 基金项目:佛山市医学类科技攻关项目（2015AB00329） |
|
| Hits: 250 |
| Download times: 183 |
| 中文摘要: |
| 摘要 目的：研究血清血管内皮生长因子(VEGF)水平与贝伐珠单抗联合化疗治疗转移性结直肠癌患者疗效的关系。方法：选取2015年2月至2016年2月间我院收治的转移性结直肠癌患者80例，按照数字随机表法将患者随机分为观察组（n=40）和对照组（n=40）。对照组给予氟尿嘧啶/奥沙利铂（FOLFOX-6）方案治疗，观察组则在此基础上加用贝伐珠单抗5 mg/kg治疗，d1，两组均进行4个化疗周期，比较两组患者临床疗效及治疗前、治疗后血清VEGF水平，并分析血清VEGF与疗效的相关性。结果：观察组有效率（RR）为52.50%（21/40），高于对照组的30.00%（12/40）（P＜0.05）。治疗前两组患者血清VEGF水平差异无统计学意义（P>0.05），治疗后两组患者血清VEGF水平均较治疗前显著降低，观察组患者血清VEGF水平显著低于对照组患者，观察组VEGF下降幅度显著高于对照组（均P＜0.05）。经秩相关分析显示，结直肠癌患者治疗后VEGF下降幅度与治疗疗效呈显著正相关（r=0.683，P=0.000）。结论：贝伐珠单抗联合化疗治疗转移性结直肠癌可显著降低患者血清VEGF水平，疗效更佳。 |
| 英文摘要: |
| ABSTRACT Objective: To study the relationship between serum vascular endothelial growth factor (vascular endothelial, growth factor, VEGF) level and the curative effect of bevacizumab combined with chemotherapy in the treatment of patients with metastatic col- orectal cancer. Methods: A total of 80 patients with metastatic colorectal cancer, who were admitted to First People's Hospital of Foshan from February 2015 to February 2016, were randomly divided into observation group (n=40) and control group (n=40). The control group was given 5-FU/oxaliplatin (FOLFOX-6), on the basis of which, the observation group were treated with bevacizumab(5 mg/kg, d1). The two groups were received 4 cycles of chemotherapy. The clinical curative effect and serum VEGF levels of the patients in the two groups before and after treatment were compared, and the correlation between serum VEGF level and curative effect was analyzed. Results: The effective rate[52.50% (21/40)] of the observation group was significantly higher than that[30.00% (12/40)] of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in serum VEGF level between the two groups before treatment (P>0.05); after treatment, the serum VEGF levels of the two groups were significantly decreased, the serum VEGF level of ob- servation group was significantly lower than that of the control group (P<0.05). The rank correlation analysis showed that there was a sig- nificantly positive correlation between the descent range of VEGF and the curative effect after treatment (r=0.683, P=0.000). Conclusion: Bevacizumab combined with chemotherapy in the treatment of metastatic colorectal cancer can significantly reduce the level of serum VEGF, and the curative effect is much better. |
|
View Full Text
View/Add Comment Download reader |
| Close |
